Research Summary
Research Summary
05/24/2024

Anthony Calabro, MA

Anthony Calabro, MA
Oxalate nephropathy is a commonly underrecognized cause of chronic kidney disease and end-stage kidney disease with multiple etiologies, including primary hyperoxaluria, enteric hyperoxaluria, or ingestion...
05/24/2024
RESEARCH SUMMARY
RESEARCH SUMMARY
05/22/2024

Anthony Calabro, MA

Anthony Calabro, MA
A recent cross-sectional, observational study compared the tau spread in people with Down syndrome and autosomal-dominant Alzheimer disease to identify tau-related differences between the two groups.
05/22/2024
research summary
research summary
05/20/2024
Researchers examined the epidemiology of hydroxymethylbilane synthase (HMBS) gene defects and activity levels among patients with acute intermittent porphyria to better understand the role of HMBS activity...
05/20/2024
FDA Alert
FDA Alert
04/18/2024

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved givinostat, a nonsteroidal oral medication, for treating patients 6 years of age or older with Duchenne muscular dystrophy.
04/18/2024
FDA Alert
FDA Alert
03/19/2024

Jessica Ganga

Jessica Ganga
The FDA approved two gene therapies, the first of their kind, to treat patients aged 12 years and older with sickle cell disease.
03/19/2024
Research Summary
Research Summary
10/26/2023

Anthony Calabro, MA

Anthony Calabro, MA
Researchers set out to determine the impact of midostaurin in adult patients with FLT3-mutated acute myeloid leukemia.
10/26/2023
FDA ALERT
FDA ALERT
04/18/2023

Jessica Ganga

Jessica Ganga
The FDA has approved a treatment for Friedreich ataxia after the results of randomized, placebo-controlled study indicate a strong effectiveness in treatment.
04/18/2023
Enzyme Replacement Therapy
Enzyme Replacement Therapy
03/17/2023

Jessica Ganga

Jessica Ganga
Following a multicenter study, the FDA has approved the first enzyme replacement therapy in the United States to treat alpha-mannosidosis.
03/17/2023
Bleeding Disorders
Bleeding Disorders
11/28/2022
The first of its kind gene therapy treatment has been approved by the FDA for adults with Hemophilia B.
11/28/2022
Genetics
Genetics
11/23/2022
The researchers set out to determine whether rare variations in certain genes contribute to the risk of developing sJIA.
11/23/2022